8:48 AM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events or dose-limiting...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >